Beyond GLP-1: Amylin-Based Pharmacotherapy and the Search for Better-Tolerated Weight-Loss Drugs.
Amylin-based therapies like cagrilintide offer a promising approach to obesity treatment, but understanding their tolerability is key to enhancing clinical utility.
Where it sits
this study against the rest of the cagrilintide (am833) corpusSummary and findings
The review discusses amylin-based pharmacotherapy as a strategy for obesity treatment, focusing on cagrilintide and other analogs. It highlights the distinct pharmacological mechanisms and receptor selectivity of these agents. The paper emphasizes the importance of understanding tolerability profiles to improve clinical utility.
Abstract
Amylin-based pharmacotherapy has re-emerged as a promising strategy for the treatment of obesity and metabolic disease with pharmacological and neural mechanisms distinct from incretin-based therapies. Amylin is a pancreatic β-cell hormone co-secreted with insulin that contributes to postprandial glucose regulation, slows gastric emptying, suppresses glucagon secretion, and promotes satiation through actions in the central nervous system. Recent advances in peptide engineering, lipidation, and reversible albumin binding have enabled the development of long-acting amylin-based agents, including cagrilintide, eloralintide, petrelintide and NN1213. These therapies differ in their pharmacokinetic properties and receptor selectivity, ranging from more selective amylin receptor agonists to dual amylin/calcitonin receptor agonists. This distinction may be critical for understanding both efficacy and tolerability, as calcitonin receptor engagement, exposure kinetics, and downstream neural circuit recruitment may influence whether reduced food intake reflects physiological satiation or aversive signaling. In this review, we summarize the biology of amylin signaling, the historical development of amylin-based therapeutics, and the emerging clinical landscape of long-acting amylin analogs. We place particular emphasis on the tolerability profile of this drug class and discuss how receptor pharmacology, hindbrain and parabrachial circuitry, species differences, and pharmacokinetic exposure may shape nausea, malaise, and emesis. Understanding how amylin-based therapies dissociate weight-loss efficacy from gastrointestinal intolerance may guide the rational design of next-generation anti-obesity drugs with improved clinical utility.
Background
Amylin-based pharmacotherapy is being explored as a treatment for obesity and metabolic diseases due to its distinct mechanisms compared to incretin-based therapies. Amylin, a hormone co-secreted with insulin, plays a role in glucose regulation and appetite suppression. This study is significant as it reviews the development and potential of long-acting amylin analogs, which may offer better tolerability and efficacy in weight management.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
The review suggests that understanding the pharmacological distinctions and receptor selectivity of amylin-based therapies is crucial for improving their clinical utility. While the potential for better-tolerated weight-loss drugs is promising, the lack of new experimental data limits the ability to draw definitive conclusions about clinical efficacy. The emphasis on tolerability profiles highlights the need for further research to dissociate weight-loss effects from gastrointestinal side effects.
Key findings
- Amylin is co-secreted with insulin and regulates postprandial glucose.
- Cagrilintide and other analogs have distinct pharmacokinetic properties.
- Receptor selectivity may influence efficacy and tolerability.
- Calcitonin receptor engagement affects food intake signaling.
- The review emphasizes tolerability profiles of amylin-based drugs.
Limitations
- Review article, no new data
- Focus on theoretical considerations
- Lacks quantitative findings
- No direct clinical trial data